Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
EyePoint Pharmaceuticals, Inc. - Common Stock
(NQ:
EYPT
)
6.520
-0.310 (-4.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about EyePoint Pharmaceuticals, Inc. - Common Stock
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
February 03, 2024
From
EyePoint Pharmaceuticals, Inc.
Via
GlobeNewswire
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
May 02, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Near the Top of Equities by Percentage Gain on 4/21
April 21, 2023
Via
Investor Brand Network
Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) Leading the Way in Monday Trading Based on Percentage Gain
March 27, 2023
Via
Investor Brand Network
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
December 28, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
December 23, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
December 16, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
December 12, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, BRP, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
December 02, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, F45, PROG, and Establishment and Encourages Investors to Contact the Firm
November 21, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, F45, PROG, and Intuit and Encourages Investors to Contact the Firm
November 11, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
November 06, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
NASDAQ:EYPT Investor Alert: Investigation over Potential Securities Laws Violations by EyePoint Pharmaceuticals, Inc.
November 02, 2022
San Diego, CA -- (SBWIRE) -- 11/02/2022 -- EyePoint Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Bragar Eagel & Squire, P.C. Is Investigating Vintage Wine, Flowserve, Cantaloupe, and EyePoint and Encourages Investors to Contact the Firm
October 31, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating FedEx, Cantaloupe, Compass, and EyePoint and Encourages Investors to Contact the Firm
October 27, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, F45 Training, and PROG and Encourages Investors to Contact the Firm
October 26, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm
October 16, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, and F45 and Encourages Investors to Contact the Firm
October 11, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Compass, EyePoint, F45, and PROG and Encourages Investors to Contact the Firm
October 06, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
August 31, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
August 31, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
August 31, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
August 31, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
August 30, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
August 30, 2022
From
The Schall Law Firm
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.